2-HOBA in Systemic Lupus Erythematosus

Inclusion Criteria: * Written informed consent * Age ≥18 years * Meeting the 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for SLE32 * No change in immunosuppressants ≥3 months * Stable prednisone (or equivalent) dose ≤ 20mg/ day for ≥ 1 month * Elevated blood pressure defined as \>120 and \< or = 160 mmHg systolic or \>80 and \< or = 110 mmHg diastolic blood pressure at screening visit * No change in anti-hypertensive dose ≥2 weeks * Willingness to stop NSAIDs for ≥2 weeks before and throughout the study * If of childbearing potential, willingness to use effective birth control throughout the study and 4 weeks after completion of the study (examples: condom, diaphragm, oral contraceptive pill, intrauterine device) Exclusion Criteria: * Pregnant or breastfeeding * Active cancer except for non-melanoma skin cancer * Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: AST or ALT \>1.5x the upper limit of normal or total bilirubin ≥1.5 mg/dl * Active infection requiring medical intervention * Major surgery in ≤ 3 months * Aspirin allergy * Use of MAO-I * Estimated creatinine clearance \<30 ml/min * Known atrial fibrillation * Severe comorbid condition